Global Myelodysplastic Syndrome Treatment Market Set to Reach USD 5,614.1 Million by 2032, Growing at a CAGR of 5.9%

Global Myelodysplastic Syndrome Treatment Market

The global myelodysplastic syndrome (MDS) treatment market is on track to experience substantial growth, with a projected compound annual growth rate (CAGR) of 5.9%. The market generated a revenue share of approximately USD 2,990.8 million in 2022 and is expected to reach around USD 5,614.1 million by 2032.

Myelodysplastic syndromes, a group of diverse bone marrow disorders characterized by ineffective blood cell production, have seen increased attention in recent years due to a rising patient population and advancements in treatment options. As awareness and understanding of MDS grow, healthcare providers are increasingly focusing on improving patient outcomes through innovative therapies.

Key factors contributing to the anticipated growth of the MDS treatment market include:

• Rising Incidence of MDS: The prevalence of myelodysplastic syndromes is on the rise, particularly among the aging population, which is driving demand for effective treatment options.
• Advancements in Treatment Options: Ongoing research and development in pharmacological therapies, including novel agents and combination treatments, are enhancing the management of MDS, providing patients with improved survival rates and quality of life.
• Increasing Investment in Healthcare: Growing investments in healthcare infrastructure and oncology research are facilitating the development and accessibility of advanced therapies for MDS.

Myelodysplastic syndromes (MDS) are conditions that can occur when the blood-forming cells in the bone marrow are damaged. This damage leads to low numbers of one or more type of blood cells. MDS is considered as a type of cancer.

Myelodysplastic syndromes are a rare group of disorders in which body no longer makes enough healthy blood cells. This disorder can also be called as “bone marrow failure disorder.”

The patient pool are more of age group of 50 or older, but it can happen to younger people, too. This syndrome is more common in men as compared to women.

According to American Society of Clinical Oncology (ASCO), approximately 13,000 people in the U.S. are diagnosed with MDS each year.

Myelodysplastic Syndrome Treatment Market: Drivers and Restraints

The Myelodysplastic Syndrome Treatment market is expected to mark a significant growth in the coming few years due to increasing mutation in treatments which cause myelodysplastic syndrome. Addition to this, growing number of patient pool of age 50 and above, and rising government support for cancer treatment tend to propel the market.

However, unawareness about such treatments is one of the major factor which is delaying the growth of this market.

Myelodysplastic Syndrome Treatment Market: Overview

The global market for myelodysplastic syndrome treatment is expected to witness high growth over the forecast period due increasing incidences of myelodysplastic syndrome. In the U.S., myelodysplastic syndromes (MDS) occur at a rate of 4.8 cases for every 100,000 people. That works out to about 13,000 new cases of MDS each year. The number of new cases diagnosed each year seems to be increasing as the average age of the population increases. (Source: American Cancer Society).

Furthermore, diagnosis techniques such as blood count, peripheral blood smear test, microscopic exams, cytochemistry, flow cytometry and immunotherapy, cytogenetics, FISH, and PCR help in the detection of MDS, also key factor which is propelling the myelodysplastic syndrome treatment market towards growth.

Myelodysplastic Syndrome Treatment Market: Regional Outlook

Geographically, global myelodysplastic syndrome treatment market is classified into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific, Japan, Middle East and Africa. North America and Europe together dominates the global myelodysplastic syndrome treatment market due to presence of large number of population suffering from bone marrow disease, rise in healthcare expenditure, and increasing demand for myelodysplastic syndrome treatment by the end users. Asia Pacific myelodysplastic syndrome treatment market is expected to be one of the fastest growing markets due to increasing number of patient with blood marrow disorder.

Myelodysplastic Syndrome Treatment Market: Key Players

The market for myelodysplastic syndrome treatment is consolidated with a presence of few strong players. Some of the players identified in global myelodysplastic syndrome treatment market include Celgene Corporation, Otsuka Holdings Co., Ltd., Sandoz, Inc., Dr. Reddy’s Laboratories, Inc., Accord Healthcare Ltd., Mylan N.V., Pfizer, Inc. etc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

The report covers exhaustive analysis on

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Value Chain

Regional analysis includes

• North America (U.S., Canada)
• Latin America (Mexico, Brazil)
• Western Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX)
• Eastern Europe (Russia, Poland, Rest of Eastern Europe)
• Asia Pacific Excluding Japan (China, India, Australia & New Zealand)
• Japan
• The Middle East and Africa (GCC, South Africa, Rest of MEA)

A Full Report Overview

Myelodysplastic Syndrome Treatment Market: Segmentation

Tentatively, global myelodysplastic syndrome treatment market has been segmented on the basis of types, treatments, patient group, and geography

Based on Type, global myelodysplastic syndrome treatment market is segmented as below:

• Refractory cytopenia with unilineage dysplasia (RCUD)
• Refractory anemia with ringed sideroblasts (RARS)
• Refractory cytopenia with multilineage dysplasia (RCMD)
• Refractory anemia with excess blasts-1 (RAEB-1)
• Refractory anemia with excess blasts-2 (RAEB-2)
• Myelodysplastic syndrome, unclassified (MDS-U)
• Myelodysplastic syndrome associated with isolated del(5q)

Based on treatment, global myelodysplastic syndrome treatment market is segmented as below:

• Chemotherapy
• Immunotherapy
• Stem cell transplantation / bone marrow transplantation
• Growth Factors

Based on patient group, global myelodysplastic syndrome treatment market is segmented as below

• Above 50 years
• Below 50 years

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:      

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube